57 pending office actions • 16 clients
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19385591 | Untitled | Regeneron Pharmaceuticals, Inc. | MERTZ, PREMA MARIA | 1674 | Non-Final OA | |
| 19312684 | Untitled | Earendil Labs Inc. | CANELLA, KAREN A | 1643 | Non-Final OA | |
| 18729020 | LIPIDIC COMPOUNDS, AND USES THEREOF | Sanofi | PIPIC, ALMA | 1617 | Non-Final OA | Jul 15, 2024 |
| 18741976 | LYME DISEASE RNA VACCINE | Sanofi | OGUNBIYI, OLUWATOSIN A | 1645 | Non-Final OA | Jun 13, 2024 |
| 18664925 | CNS DELIVERY OF MRNA AND USES THEREOF | Translate Bio, Inc. | DAVIS, BRIAN J | 1614 | Non-Final OA | May 15, 2024 |
| 18616452 | MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY | Kymab Limited | GILL, RACHEL B | 1671 | Final Rejection | Mar 26, 2024 |
| 18609160 | RIBOSE CATIONIC LIPIDS | Translate Bio, Inc. | SHOMER, ISAAC | 1612 | Non-Final OA | Mar 19, 2024 |
| 18592425 | ANTI-PD-L1 AND IL-2 CYTOKINES | Kymab Limited | ROONEY, NORA MAUREEN | 1641 | Non-Final OA | Feb 29, 2024 |
| 18407331 | METHODS FOR REDUCING OR ELIMINATING THE NEED FOR LIPOPROTEIN APHERESIS IN PATIENTS WITH HYPERLIPIDEMIA BY ADMINISTERING ALIROCUMAB | Regeneron Pharmaceuticals, Inc. | WEN, SHARON X | 1641 | Non-Final OA | Jan 08, 2024 |
| 18495182 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST | Regeneron Pharmaceuticals, Inc. | MERTZ, PREMA MARIA | 1674 | Non-Final OA | Oct 26, 2023 |
| 18286029 | IMPROVED COMPOSITIONS FOR DELIVERY OF MRNA | Translate Bio, Inc. | ZARA, JANE J | 1637 | Non-Final OA | Oct 06, 2023 |
| 18470507 | METHODS FOR QUANTIFYING DRUG CONCENTRATION IN A PRODRUG COMPOSITION | Genzyme Corporation | ADAMS, MICHELLE | 1797 | Non-Final OA | Sep 20, 2023 |
| 18459995 | ANTIBODIES, COMBINATIONS COMPRISING ANTIBODIES, BIOMARKERS, USES & METHODS | Kymab Limited | HADDAD, MAHER M | 1641 | Final Rejection | Sep 01, 2023 |
| 18455756 | TARGETED INHIBITION USING ENGINEERED OLIGONUCLEOTIDES | Mirecule, Inc. | CHONG, KIMBERLY | 1636 | Non-Final OA | Aug 25, 2023 |
| 18364906 | ANTIBODIES, USES & METHODS | Kymab Limited | HADDAD, MAHER M | 1641 | Final Rejection | Aug 03, 2023 |
| 18364103 | OPTIMIZED FACTOR VIII GENES | BIOVERATIV THERAPEUTICS INC. | NGUYEN, QUANG | 1631 | Non-Final OA | Aug 02, 2023 |
| 18358601 | THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOF | BIOVERATIV THERAPEUTICS INC. | BEANE, RANDALL L | 1654 | Final Rejection | Jul 25, 2023 |
| 18352615 | METHODS AND COMPOSITIONS FOR DELIVERING MRNA CODED ANTIBODIES | Translate Bio, Inc. | MCGARRY, SEAN | 1635 | Non-Final OA | Jul 14, 2023 |
| 17926123 | COMPOSITIONS AND METHODS FOR TREATING NONINFLAMMATORY PAIN IN SUBJECTS WITH RHEUMATOID ARTHRITIS | Sanofi Biotechnology | OUSPENSKI, ILIA I | 1644 | Non-Final OA | Jun 15, 2023 |
| 18207609 | MRNA THERAPY FOR POMPE DISEASE | Translate Bio, Inc. | MCGARRY, SEAN | 1635 | Final Rejection | Jun 08, 2023 |
| 18324668 | ANTI-BCMA ANTIBODIES | Sanofi | PETERS, ALEC JON | 1641 | Non-Final OA | May 26, 2023 |
| 18319279 | SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES | Genzyme Corporation | PUTTLITZ, KARL J | 1646 | Non-Final OA | May 17, 2023 |
| 18308778 | MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123 | Sanofi | HAM, JIEUN | 1643 | Non-Final OA | Apr 28, 2023 |
| 18247607 | METHODS FOR PURIFICATION OF MESSENGER RNA | Translate Bio, Inc. | LEE, HOI YAN NMN | 1693 | Non-Final OA | Mar 31, 2023 |
| 18246263 | PIPERAZINE-BASED CATIONIC LIPIDS | Translate Bio, Inc. | ANDERSON, REBECCA L | 1626 | Non-Final OA | Mar 22, 2023 |
| 17969033 | METHODS FOR TREATING PRURIGO NODULARIS BY ADMINISTERING AN IL-4R ANTAGONIST | Regeneron Pharmaceuticals, Inc. | NATARAJAN, MEERA | 1643 | Final Rejection | Mar 02, 2023 |
| 18016625 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | Sanofi Pasteur | ROZOF, TIMOTHY R | 1625 | Non-Final OA | Jan 17, 2023 |
| 17923839 | COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA | Translate Bio, Inc. | SHIN, DANA H | 1635 | Non-Final OA | Nov 07, 2022 |
| 18052600 | RESPIRATORY SYNCTIAL VIRUS RNA VACCINE | Sanofi | PYLA, EVELYN Y | 1633 | Non-Final OA | Nov 04, 2022 |
| 18045995 | FGFR3 ANTIBODIES AND METHODS OF USE | Genzyme Corporation | ALLEN, MARIANNE P | 1647 | Non-Final OA | Oct 12, 2022 |
| 17907739 | PHENOLIC ACID LIPID BASED CATIONIC LIPIDS | Translate Bio, Inc. | CUTLIFF, YATE KAI RENE | 1692 | Non-Final OA | Sep 29, 2022 |
| 17915215 | Targeted Inhibition Using Engineered Oligonucleotides | Mirecule, Inc. | MCKILLOP, JOHN CHARLES | 1637 | Non-Final OA | Sep 28, 2022 |
| 17934259 | COMPOSITIONS AND METHODS FOR TREATING JUVENILE IDIOPATHIC ARTHRITIS | Regeneron Pharmaceuticals, Inc. | XIE, XIAOZHEN | 1674 | Non-Final OA | Sep 22, 2022 |
| 17821359 | OPTIMIZED FACTOR VIII GENES | BIOVERATIV THERAPEUTICS INC. | DACE DENITO, ALEXANDRA GERALDINE | 1636 | Final Rejection | Aug 22, 2022 |
| 17821356 | CLOSED-END DNA PRODUCTION WITH INVERTED TERMINAL REPEAT SEQUENCES | BIOVERATIV THERAPEUTICS INC. | GROOMS, TIFFANY NICOLE | 1637 | Final Rejection | Aug 22, 2022 |
| 17872225 | METHODS FOR TREATING CHRONIC SPONTANEOUS URTICARIA BY ADMINISTERING AN IL-4R ANTAGONIST | Regeneron Pharmaceuticals, Inc. | PATTERSON, SARAH COOPER | 1675 | Final Rejection | Jul 25, 2022 |
| 17843445 | MULTIVALENT INFLUENZA VACCINES | Sanofi Pasteur Inc. | HILL, MYRON G | 1671 | Final Rejection | Jun 17, 2022 |
| 17835719 | Methods for Purification of Messenger RNA | Translate Bio, Inc. | GUSSOW, ANNE | 1683 | Final Rejection | Jun 08, 2022 |
| 17775446 | BIPARATOPIC CD73 ANTIBODIES | Genzyme Corporation | AEDER, SEAN E | 1642 | Final Rejection | May 09, 2022 |
| 17727309 | ANTI-ICOS ANTIBODIES | Kymab Limited | OUSPENSKI, ILIA I | 1644 | Non-Final OA | Apr 22, 2022 |
| 17725228 | SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD | Kymab Limited | OUSPENSKI, ILIA I | 1644 | Non-Final OA | Apr 20, 2022 |
| 17592335 | MRNA THERAPY FOR THE TREATMENT OF OCULAR DISEASES | Translate Bio, Inc. | NGUYEN, QUANG | 1631 | Non-Final OA | Feb 03, 2022 |
| 17587941 | FACTOR VIII-FC CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF | BIOVERATIV THERAPEUTICS INC. | SZPERKA, MICHAEL EDWARD | 1641 | Final Rejection | Jan 28, 2022 |
| 17576562 | ENGINEERED ITR SEQUENCES AND METHODS OF USE | BIOVERATIV THERAPEUTICS INC. | SHUKLA, RAM R | 1635 | Non-Final OA | Jan 14, 2022 |
| 17572260 | Nuclease Resistant Polynucleotides and Uses Thereof | Translate Bio, Inc. | WHISENANT, ETHAN C | 1683 | Final Rejection | Jan 10, 2022 |
| 17615732 | MODIFIED DOSAGE OF SUBCUTANEOUS TOCILIZUMAB FOR RHEUMATOID ARTHRITIS | Regeneron Pharmaceuticals, Inc. | HECK, BRYAN WILLIAM | 1643 | Final Rejection | Dec 01, 2021 |
| 17605343 | THIOESTER CATIONIC LIPIDS | Translate Bio, Inc. | POPA, ILEANA | 1633 | Non-Final OA | Oct 21, 2021 |
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | Translate Bio, Inc. | POPA, ILEANA | 1633 | Final Rejection | Oct 12, 2021 |
| 17403592 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | Genzyme Corporation | LEE, HOI YAN NMN | 1693 | Final Rejection | Aug 16, 2021 |
| 17286113 | PUMPLESS ENCAPSULATION OF MESSENGER RNA | Translate Bio, Inc. | LUK, EMMANUEL S | 1744 | Non-Final OA | Apr 16, 2021 |
| 17183904 | COMPOSITIONS COMPRISING IL6R ANTIBODIES FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF USING SAME | Regeneron Pharmaceuticals, Inc. | FAUST, AMBER KATHLEEN | 1643 | Non-Final OA | Feb 24, 2021 |
| 17172527 | METHODS AND COMPOSITIONS FOR MESSENGER RNA PURIFICATION | Translate Bio, Inc. | POHNERT, STEVEN C | 1683 | Non-Final OA | Feb 10, 2021 |
| 17162356 | MODIFIED ADENO-ASSOCIATED VIRAL CAPSID PROTEINS FOR OCULAR GENE THERAPY AND METHODS OF USE THEREOF | Genzyme Corporation | PENNINGTON, KATIE LEIGH | 1634 | Non-Final OA | Jan 29, 2021 |
| 17112198 | METHODS FOR TREATING COPD BY ADMINISTERING AN IL-33 ANTAGONIST | Regeneron Pharmaceuticals, Inc. | BENAVIDES, JENNIFER ANN | 1675 | Final Rejection | Dec 04, 2020 |
| 17076195 | COMPOSITIONS, METHODS AND USES OF MESSENGER RNA | Translate Bio, Inc. | SHIN, DANA H | 1635 | Final Rejection | Oct 21, 2020 |
| 16965895 | USE OF LENTIVIRAL VECTORS EXPRESSING FACTOR VIII | BIOVERATIV THERAPEUTICS INC. | MARVICH, MARIA | 1634 | Final Rejection | Jul 29, 2020 |
| 15505056 | COMPOSITIONS FOR IMPROVING THE HEALTH RELATED QUALITY OF LIFE OF RHEUMATOID ARTHRITIS PATIENTS | Regeneron Pharmaceuticals, Inc. | JIANG, DONG | 1674 | Non-Final OA | Feb 17, 2017 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial